Abdelaziz Moustafa M, Hefnawy Amr, Anter Asem, Abdellatif Menna M, Khalil Mahmoud A F, Khalil Islam A
Department of Bioengineering, The University of Kansas, Lawrence, Kansas 66045, United States.
Smyth Laboratory, College of Pharmacy, University of Texas at Austin, Austin, Texas 78712, United States.
ACS Omega. 2022 Aug 16;7(34):30161-30170. doi: 10.1021/acsomega.2c03226. eCollection 2022 Aug 30.
Drug resistance is a global health challenge with thousands of deaths annually caused by bacterial multidrug resistance (MDR). Efforts to develop new antibacterial molecules do not meet the mounting needs imposed by the evolution of MDR. An alternative approach to overcome this challenge is developing targeted formulations that can enhance the therapeutic efficiency and limit side effects. In this aspect, vancomycin is a potent antibacterial agent that has inherent bacterial targeting properties by binding to the D-Ala-D-Ala moiety of the bacterial peptidoglycan. However, the use of vancomycin is associated with serious side effects that limit its clinical use. Herein, we report the development of vancomycin-conjugated magnetic nanoparticles using a simple conjugation method for targeted antibacterial activity. The nanoparticles were synthesized using a multistep process that starts by coating the nanoparticles with a silica layer, followed by binding an amide linker and then binding the vancomycin glycopeptide. The developed vancomycin-conjugated magnetic nanoparticles were observed to exhibit a spherical morphology and a particle size of 16.3 ± 2.6 nm, with a silica coating thickness of 5 nm and a total coating thickness of 8 nm. The vancomycin conjugation efficiency on the nanoparticles was measured spectrophotometrically to be 25.1%. Additionally, the developed formulation retained the magnetic activity of the nanoparticles, where it showed a saturation magnetization value of 51 emu/g, compared to 60 emu/g for bare magnetic nanoparticles. The in vitro cell biocompatibility demonstrated improved safety where vancomycin-conjugated nanoparticles showed IC of 183.43 μg/mL, compared to a much lower value of 54.11 μg/mL for free vancomycin. While the antibacterial studies showed a comparable activity of the developed formulation, the minimum inhibitory concentration was 25 μg/mL, compared to 20 μg/mL for free vancomycin. Accordingly, the reported formulation can be used as a platform for the targeted and efficient delivery of other drugs.
耐药性是一项全球性的健康挑战,每年有数千人死于细菌多重耐药性(MDR)。开发新型抗菌分子的努力无法满足MDR演变带来的日益增长的需求。克服这一挑战的另一种方法是开发能够提高治疗效率并限制副作用的靶向制剂。在这方面,万古霉素是一种强效抗菌剂,通过与细菌肽聚糖的D-Ala-D-Ala部分结合而具有内在的细菌靶向特性。然而,万古霉素的使用会带来严重的副作用,限制了其临床应用。在此,我们报告了使用一种简单的偶联方法开发用于靶向抗菌活性的万古霉素偶联磁性纳米颗粒。纳米颗粒通过多步工艺合成,首先用二氧化硅层包覆纳米颗粒,然后连接酰胺连接体,再连接万古霉素糖肽。观察到所开发的万古霉素偶联磁性纳米颗粒呈现球形形态,粒径为16.3±2.6nm,二氧化硅涂层厚度为5nm,总涂层厚度为8nm。通过分光光度法测定纳米颗粒上的万古霉素偶联效率为25.1%。此外,所开发的制剂保留了纳米颗粒的磁性活性,其饱和磁化强度值为51emu/g,而裸磁性纳米颗粒为60emu/g。体外细胞生物相容性表明安全性有所提高,万古霉素偶联纳米颗粒的IC为183.43μg/mL,而游离万古霉素的值低得多,为54.11μg/mL。虽然抗菌研究表明所开发制剂的活性相当,其最低抑菌浓度为25μg/mL,而游离万古霉素为20μg/mL。因此,所报道的制剂可作为其他药物靶向高效递送的平台。